ProMIS Neurosciencesの価格/販売
ProMIS Neurosciencesの価格/販売は何ですか。
ProMIS Neurosciences, Inc.の価格/販売は3,174.59です。
価格/販売の定義は何ですか。
価格対売上比率は、収益と比較した会社の株価です。
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
OTCのセクタHealth Careにおける価格/販売の企業と比べるProMIS Neurosciences
ProMIS Neurosciencesは何をしますか。
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciencesと類似の価格/販売
- Fortune Mineralsの価格/販売は2,925.69です。
- CropLogicの価格/販売は3,017.98です。
- Australian Vanadiumの価格/販売は3,057.75です。
- Clean Power Hydrogen Plcの価格/販売は3,067.66です。
- Burley Minerals Ltdの価格/販売は3,106.03です。
- Denali Therapeutics Incの価格/販売は3,111.82です。
- ProMIS Neurosciencesの価格/販売は3,174.59です。
- Awale Resourcesの価格/販売は3,322.64です。
- Jindal Photoの価格/販売は3,418.44です。
- Evrim Resourcesの価格/販売は3,436.94です。
- Wilton Resourcesの価格/販売は3,448.90です。
- Actinium Pharmaceuticals Incの価格/販売は3,463.84です。
- Transport of Indiaの価格/販売は3,501.72です。